|
KMID : 0923620140140020081
|
|
Immune Network
2014 Volume.14 No. 2 p.81 ~ p.88
|
|
|
Preclinical Efficacy and Mechanisms of Mesenchymal Stem Cells in Animal Models of Autoimmune Diseases
|
|
Lee Hong-Kyung
Lim Sang-Hee
Chung In-Sung
Park Yun-Soo
Park Mi-Jeong
Kim Ju-Young
Kim Yong-Guk
Hong Jin-Tae
Kim Young-Soo
Han Sang-Bae
|
|
|
Abstract
|
|
|
|
Mesenchymal stem cells (MSCs) are present in diverse tis-sues and organs, including bone marrow, umbilical cord, adi-pose tissue, and placenta. MSCs can expand easily in vitro and have regenerative stem cell properties and potent im-munoregulatory activity. They inhibit the functions of den-dritic cells, B cells, and T cells, but enhance those of regu-latory T cells by producing immunoregulatory molecules such as transforming growth factor-?, hepatic growth factors, prostaglandin E2, interleukin-10, indolamine 2,3-dioxyge-nase, nitric oxide, heme oxygenase-1, and human leukocyte antigen-G. These properties make MSCs promising ther-apeutic candidates for the treatment of autoimmune dis-eases. Here, we review the preclinical studies of MSCs in an-imal models for systemic lupus erythematosus, rheumatoid arthritis, Crohn’s disease, and experimental autoimmune en-cephalomyelitis, and summarize the underlying immunor-egulatory mechanisms.
|
|
|
KEYWORD
|
|
|
Mesenchymal stem cells, Immunoregulation, Autoimmune diseases
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|
|